The authors conducted an immunohistochemical study with antibodies to Her-2/neu and tenascin in urothelial bladder carcinoma. The samples taken from 32 patients with stages Т2b/T3a, N0 and N+ urinary bladder carcinoma were studied. The tumor cells showed hyper-expression of the oncoprotein Her-2/neu in 6 out of 13 patients with metastases to the regional lymph nodes (T3b и T3a) and in 2 out of 7 tumors (Т3а) without lymph node involvement. Quantitative assessment of the reaction with tenascin antibodies revealed that in the metastatic lymph node involvement group, the staining area was much larger than that in metastasis-free group and it averaged 49.83 and 44.21% and 11.27 and 15.7%, respectively. Comparison analysis of Her-2/neu and tenascin expression revealed no clinically significant regularities. The study of the intercellular matrix showed a high correlation between the increase in the share of tenascin-expressing and/or containing structures and the rise in the metastatic activity of a tumor.
